Robert Young earned a BSc from the University of Victoria (1967) and a PhD from the University of British Columbia (1971). He completed his Postdoctoral studies (1971-76) at Imperial College (London), University of Adelaide (Australia), and at UBC (Vancouver). Dr. Young held the position of Research Associate at the Institut de Chimie des Substances Naturelles in Gif-sur-Yvette, France (1976-77) and from 1977 until 2006 worked in various capacities with Merck Frosst Canada & Co., rising to Vice-President and Head of the Medicinal Chemistry Department. He was Acting Site Head at the Merck Frosst Centre for Therapeutic Research (Montreal) and at MSD, Terlings Park Neurosciences Centre in the UK. Since 2007, Dr. Young is a Professor of Chemistry and Merck Frosst-B.C. Leadership Chair in Pharmaceutical Genomics, Bioinformatics and Drug Discovery in the Chemistry Department, Simon Fraser University. Dr. Young’s industrial career focused on the design and synthesis of novel drugs for asthma, inflammation, and osteoporosis, and he is most noted for his part in the discovery of the asthma drug, SingulairTM and of the anti-inflammatory drug ArcoxiaTM.
He is author of more than 200 publications, review articles, and patents.
Selected honours: Order of Canada (MC), Fellow of the Royal Society of Canada, the Chemical Institute of Canada and the Canadian Society of Pharmaceutical Sciences (CSPS), Prix Galien, “Heroes of Chemistry” Award (American Chemical Society), Genome BC Leadership Award, and Health Research Institute Medal of Honour. President of the Canadian Society for Pharmaceutical Sciences (2012-2013).